Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30

$8.02−0.60 (-6.96%)

Close on Nov 12, 2026Market cap $291.06MP/E –Yield –

Evommune enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Evommune's enterprise value was $111.96M on Nov 11, 2026, against -$43.86M a year earlier.

Period	Period end	Value	Change
2026	Nov 11, 2026	$111.96M	–
2025	Dec 31, 2025	-$49.44M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is EVMN.

Revenue growth-100.0% · median 320.4%

Advertisement
300 × 250

See a number that looks wrong?